Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(0.47)
# 3,873
Out of 4,820 analysts
8
Total ratings
37.5%
Success rate
-26.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Initiates: Underweight | $8 | $14.59 | -45.17% | 1 | Apr 17, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $19 → $17 | $7.35 | +131.29% | 3 | Mar 6, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $10.45 | +215.79% | 2 | Feb 28, 2025 | |
| RCUS Arcus Biosciences | Initiates: Overweight | $29 | $8.28 | +250.24% | 1 | Oct 8, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $21.37 | +59.14% | 1 | May 3, 2024 |
Bicara Therapeutics
Apr 17, 2025
Initiates: Underweight
Price Target: $8
Current: $14.59
Upside: -45.17%
iTeos Therapeutics
Mar 6, 2025
Maintains: Overweight
Price Target: $19 → $17
Current: $7.35
Upside: +131.29%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $10.45
Upside: +215.79%
Arcus Biosciences
Oct 8, 2024
Initiates: Overweight
Price Target: $29
Current: $8.28
Upside: +250.24%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $21.37
Upside: +59.14%